OligoBio Completes Pre-A+ Financing to Accelerate Construction of Nucleic Acid Drug Production Facility

Recently,Suzhou Olipharma Technology Co., Ltd. (hereinafter referred to as "Olipharma")Announced the completion byQingSong Capital and Yida CapitalCo-investment in the Pre-A+ round, existing shareholdersMatrix PartnersContinue to invest. The proceeds of this offering will be mainly used forConstruction of a Hundred-Kilogram Scale Small Nucleic Acid Drug Production Base, in order to better meet the CDMO needs of pharmaceutical companies in China and abroad for small nucleic acid drugs from clinical to commercial production stages.

Olipharma was founded in August 2021, focusing on providing "one-stop" CDMO services for global pharmaceutical companies, including the design and screening of small nucleic acid drugs, laboratory R&D, process and analytical development, CMC services, API production, and drug registration. The company's technical team mainly comes fromOne of the earliest teams in China to develop small nucleic acid drug production processes and conduct CMC research.`, has深耕ed the field for more than a decade, possessing the most extensive experience in project development and product registration within the industry.`

Established for a year and a half, Olipharma has provided high-quality services to dozens of small nucleic acid innovative drug companies, with an output value reaching tens of millions of yuan. Currently, the company has a 1000㎡ R&D center in Kunshan, Suzhou, where it has built four core technology platforms leading in the industry: a solid-phase nucleic acid synthesis platform, a chemical modification and conjugation platform, a process development and analysis platform, and a CMC pharmaceutical research platform.And has established a 3,000-square-meter pilot platform for small nucleic acid drugs that meets GMP standards in the Wuzhong District of Suzhou, focusing on helping customers address key challenges such as scaling up production processes and CMC pharmaceutical research for small nucleic acid drugs.In addition, the company has a complete small nucleic acid drug production platform and system, equipped with a full set of mainstream nucleic acid synthesis instruments such as AKTA Oligo 100/150/400/2000/Process, covering the entire process of small nucleic acid drugs from research and development to registration and market launch.

After the completion of this round of financing, Olipharma willAccelerate the Construction of Hundred-Kilogram-Level Production Base for Small Nucleic Acid Drugs and Initiate Global Layout, with the service philosophy of compliance, quality, reliability, and efficiency, help customers overcome the difficulties in drug development, accelerate product registration and market entry, and jointly promote the entire process of small nucleic acid drugs from preclinical to commercial production.

Olipharma Founder Zhao HaiExpressed: "We are extremely grateful for the recognition from our clients and investment institutions towards Olipharma! Over the past year, the Olipharma team has worked hard, completing all kinds of projects entrusted by clients with high quality and efficiency, and overcoming various 'challenges'; In the future, we will use the raised funds to build a high-standard small nucleic acid drug production platform and system in China, in order to better serve small nucleic acid innovative drug companies and contribute Chinese strength to the development of the industry."

Li Jing, Project Director of ClearPine CapitalExpressed: "We are delighted to participate in Olipharma's current round of financing. With the vigorous development of nucleic acid drugs in technological and clinical application fields in recent years, the industry has entered a new and significant phase. A specialized one-stop CDMO platform will play a crucial nodal role in this process. The core team at Olipharma has extensive experience and deep insights into the process development and industrialization of nucleic acid drugs. ClearPine Capital, along with its strategic partners, consistently focuses on and supports the development and innovation of the supply chain. We look forward to Olipharma accelerating the construction of a leading production technology platform and service quality system in the industry under the support of this round of financing, empowering the R&D and commercialization of the global new drug industry, providing better solutions for clients, and bringing more efficient and accessible advanced therapies to patients."

Yida Capital Partner Zhang Lu"Nucleic acid drug industry chain is a field that Yida Capital has long been paying attention to and optimistic about. We are very honored to participate in this round of investment in Olipharma. Zhao Hai, the general manager of Olipharma, and its core team have accumulated more than ten years of CMC pharmaceutical research and industrialization experience in the domestic small nucleic acid drug field. Not long after starting their business, they have already gathered a group of high-quality domestic customers and are actively expanding into overseas markets. We look forward to the Olipharma team, under the leadership of General Manager Zhao, accelerating capacity layout, improving system construction, providing high-quality services to global customers, and striving to become an excellent one-stop CDMO service provider for small nucleic acid drugs, contributing to the rapid development of China's nucleic acid drug industry."

Sun Linghao, Managing Director of Matrix Partners"As the first institutional investor in Olipharma, over the past year, we have witnessed the highly efficient execution and rapid growth of Mr. Zhao's team. Despite the severe external environment in 2022, the company still achieved several-fold business growth and established long-term cooperation with multiple high-quality clients. We will continue to empower the company through the Matrix Life Science Tools ecosystem and look forward to Olipharma becoming a leading brand in the nucleic acid drug production and service field."

Qingsong Capital is a venture private equity investment institution focused on biotechnology and healthcare. The management team has a deep background in the medical industry and extensive experience in private equity investment. Qingsong Capital is committed to growing together with the most innovative biomedicine companies, promoting technological and commercial innovation in China's life sciences and healthcare industries; adhering to research-driven investment, deeply participating in the development of invested companies, and concentrating on biotechnology, pharmaceuticals, medical devices, innovative medical services, as well as the intersection of the broader health industry with cutting-edge technology.

Yida Capital was established through the internal mixed-ownership reform of Jiangsu High-Tech Investment Group, a well-known veteran venture capital institution. It ranks among the top in the industry in terms of industry research capabilities, asset management scale, and investment specialization, and is one of the most influential venture capital institutions in China.

In the past three years, Yida Capital has consistently ranked in prestigious lists by Zero2IPO Group, ChinaVenture, Securities Times, China Venture Capital Association, Forbes, and others, winning awards such as "Annual China Venture Capital Institution," "Best China Venture Capital Institution," "Most Competitive Venture Capital Institution," "Outstanding Achievement Award for Excellent Venture Capital Institutions," and "Top 10 Best Venture Capital Institutions," firmly maintaining its position in the top tier of venture capital institutions in China.

Matrix Partners was founded in 2008 and is a top venture capital firm that has long focused on early-stage and early-growth investments within the industry. It concentrates on investments in new technologies, hard tech, industrial digitalization, healthcare, frontier technologies, new consumption, and other fields. To date, it has invested in over 700 companies, including XPeng Motors, Li Auto, XGIMI Technology, Ronbay Technology, Hychen Energy Storage, PingCAP, Beisen, SemiDrive Technologies, Taimei Medical Technology, Beast, Self-heating Pot, Jane Eyre, Magna Robotics, and more.